ConRett

ConRett is a biotechnology company dedicated to developing a curative treatment for Rett syndrome, a severe neurodevelopmental disorder. Launched by the Rett Syndrome Research Trust (RSRT), the company leverages advanced RNA editing technology to repair mutations in the MECP2 gene. By targeting the underlying genetic cause of the disease at the RNA level, ConRett aims to restore functional protein levels without the risks associated with traditional gene replacement therapies. The company's approach focuses on site-directed RNA editing to correct specific mutations common in the Rett patient population. ConRett represents a strategic effort to translate academic breakthroughs into a clinical-stage pipeline.